Myleran

conditioning regimens for allogeneic stem cell transplantation therapy, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Thrombocythemia, Essential + 2 more
Treatment
3 FDA approvals
20 Active Studies for Myleran

What is Myleran

BusulfanThe Generic name of this drug
Treatment SummaryBusulfan is a medication used to reduce the activity of bone marrow, usually prescribed as a palliative treatment for chronic myeloid leukemia. Although it provides relief of symptoms, it does not bring about permanent remission. The National Toxicology Program has classified busulfan as a known carcinogen.
Myleranis the brand name
Myleran Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Myleran
Busulfan
1985
22

Approved as Treatment by the FDA

Busulfan, also known as Myleran, is approved by the FDA for 3 uses including allogeneic hematopoietic stem cell transplant, Chronic myelogenous leukemia and Leukemia, Myelogenous, Chronic, BCR-ABL Positive .
allogeneic hematopoietic stem cell transplant, Chronic myelogenous leukemia
Used to treat allogeneic hematopoietic stem cell transplant, Chronic myelogenous leukemia in combination with Cyclophosphamide
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Used to treat allogeneic hematopoietic stem cell transplant, Chronic myelogenous leukemia in combination with Cyclophosphamide
conditioning regimens for allogeneic stem cell transplantation therapy
Used to treat conditioning regimens for allogeneic stem cell transplantation therapy in combination with Cyclophosphamide

Effectiveness

How Myleran Affects PatientsBusulfan is a drug used to treat cancer and belongs to a class of drugs called alkylating agents. These drugs work by attaching alkyl groups to certain molecules, which prevents cells from replicating and dividing. In addition, alkylating agents can alter the coding of DNA, which can lead to cell death. It is believed that the overexpression of a certain enzyme (MGST2) may make some people resistant to busulfan, although the exact role of MGST2 in busulfan metabolism is unknown.
How Myleran works in the bodyBusulfan works by damaging DNA. When it enters the cell, it is broken down and releases two carbonium ions. These ions then attach to and damage DNA molecules, preventing the cell from making copies of itself and reproducing. The damage caused by busulfan is irreversible and the cell eventually dies.

When to interrupt dosage

The recommended measure of Myleran is contingent upon the identified condition, such as Polycythemia Vera (PV), conditioning regimens for allogeneic stem cell transplantation therapy and Leukemia. The quantity of dosage depends on the technique of delivery, as outlined in the table beneath.
Condition
Dosage
Administration
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
2.0 mg, , 6.0 mg/mL, 60.0 mg
, Oral, Tablet, film coated, Tablet, film coated - Oral, Solution, Intravenous, Solution - Intravenous, Tablet - Oral, Tablet, Injection, Injection - Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Injection, solution - Intravenous, Injection, solution
Polycythemia Vera
2.0 mg, , 6.0 mg/mL, 60.0 mg
, Oral, Tablet, film coated, Tablet, film coated - Oral, Solution, Intravenous, Solution - Intravenous, Tablet - Oral, Tablet, Injection, Injection - Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Injection, solution - Intravenous, Injection, solution
conditioning regimens for allogeneic stem cell transplantation therapy
2.0 mg, , 6.0 mg/mL, 60.0 mg
, Oral, Tablet, film coated, Tablet, film coated - Oral, Solution, Intravenous, Solution - Intravenous, Tablet - Oral, Tablet, Injection, Injection - Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Injection, solution - Intravenous, Injection, solution
Thrombocythemia, Essential
2.0 mg, , 6.0 mg/mL, 60.0 mg
, Oral, Tablet, film coated, Tablet, film coated - Oral, Solution, Intravenous, Solution - Intravenous, Tablet - Oral, Tablet, Injection, Injection - Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Injection, solution - Intravenous, Injection, solution
Leukemia
2.0 mg, , 6.0 mg/mL, 60.0 mg
, Oral, Tablet, film coated, Tablet, film coated - Oral, Solution, Intravenous, Solution - Intravenous, Tablet - Oral, Tablet, Injection, Injection - Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Injection, solution - Intravenous, Injection, solution

Warnings

Myleran has one contraindication and should not be administered in conjunction with any of the states listed in the table below.Myleran Contraindications
Condition
Risk Level
Notes
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Do Not Combine
There are 20 known major drug interactions with Myleran.
Common Myleran Drug Interactions
Drug Name
Risk Level
Description
2-Methoxyethanol
Major
The risk or severity of adverse effects can be increased when Busulfan is combined with 2-Methoxyethanol.
9-(N-methyl-L-isoleucine)-cyclosporin A
Major
The risk or severity of adverse effects can be increased when Busulfan is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A.
Abetimus
Major
The risk or severity of adverse effects can be increased when Busulfan is combined with Abetimus.
Acteoside
Major
The risk or severity of adverse effects can be increased when Busulfan is combined with Acteoside.
Aldosterone
Major
The risk or severity of adverse effects can be increased when Busulfan is combined with Aldosterone.
Myleran Toxicity & Overdose RiskSigns of an overdose on ibuprofen include an allergic reaction, signs of internal bleeding, sudden weakness or exhaustion, persistent coughing or difficulty breathing, stomach or joint pain, severe nausea or diarrhea, dizziness or confusion, skin discoloration, and chills. In serious cases, a person may faint or even lose consciousness.
image of a doctor in a lab doing drug, clinical research

Myleran Novel Uses: Which Conditions Have a Clinical Trial Featuring Myleran?

56 active clinical trials are underway to investigate the potential of Myleran to ameliorate Thrombocythemia, Essential Leukemia and Polycythemia Vera (PV).
Condition
Clinical Trials
Trial Phases
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
0 Actively Recruiting
Leukemia
156 Actively Recruiting
Phase 1, Phase 2, Phase 3, Not Applicable, Early Phase 1, Phase 4
Thrombocythemia, Essential
25 Actively Recruiting
Phase 2, Phase 1, Phase 3
Polycythemia Vera
0 Actively Recruiting
conditioning regimens for allogeneic stem cell transplantation therapy
0 Actively Recruiting

Myleran Reviews: What are patients saying about Myleran?

5Patient Review
8/27/2016
Myleran for Type of Leukemia - Chronic Myelogenous Leukemia
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about myleran

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is myleran used for?

"Myleran is a medication used to improve the quality of life and relieve cancer symptoms for people with chronic myelogenous leukemia. It is classified as an alkylating agent."

Answered by AI

What is busulfan used for?

"Busulfan is used in combination with cyclophosphamide to prepare a person for allogeneic hematopoietic progenitor cell transplantation, which is a treatment for chronic myelogenous leukemia. Busulfan is an alkylating agent, a group of medicines that work by causing changes in the DNA of cells."

Answered by AI

What is paraplatin used for?

"Paraplatin is a medication used to treat ovarian cancer, as well as other types of cancer such as lung, head and neck, endometrial, esophageal, bladder, breast, and cervical cancer. It is also used to treat central nervous system or germ cell tumors, osteogenic sarcoma, and to prepare for a stem cell or bone marrow transplant."

Answered by AI

Is Myleran chemotherapy?

"Myleran is a chemotherapy drug that is used to treat cancer."

Answered by AI

Clinical Trials for Myleran

Image of First Ascent Biomedical in Miami, United States.

xDRIVE Tumor Profiling for Cancer

Any Age
All Sexes
Miami, FL
Through this study funded by the Florida Cancer Innovation Fund, First Ascent will demonstrate state-wide feasibility of providing xDRIVE Functional Precision Medicine + Artificial Intelligence platform by assessing patient clinical benefit and health economics impacts. As this is a feasibility study, results will be returned to the physician and the physician may use the data to inform the next line of treatment. The investigator will run a prospective single-arm feasibility study providing the xDRIVE FPM AI platform to n = 210+ cancer patients throughout the state of Florida, especially those from underserved populations (pediatric patients and patients in Black, Brown, Hispanic, and rural communities).
Recruiting
Has No Placebo
First Ascent BiomedicalFirst Ascent Biomedical Inc.
Image of Brigham and Women's Hospital in Boston, United States.

Tagraxofusp + Venetoclax + Azacitidine for Acute Myeloid Leukemia

18+
All Sexes
Boston, MA
The purpose of this research study is to test the safety and efficacy of a new drug combination with three agents, azacitidine, venetoclax and tagraxofusp. Leftover (residual) leukemia disease that is not visible by eye can be increase the chance of disease recurrence. This research study is to determine if the combination therapy can safely help to control residual Acute Myeloid Leukemia (AML) and to prevent disease recurrence. The names of the study drugs involved in this study are: * Tagraxofusp (a type of CD123-directed cytotoxin) * Azacitidine (a type of standard of care cytidine nucleoside analog) * Venetoclax (a type of standard of care BCL-2 inhibitor)
Phase 1 & 2
Recruiting
Brigham and Women's Hospital (+1 Sites)Jacqueline Garcia, MDStemline Therapeutics, Inc.
Image of Houston Methodist Neal Cancer Center in Houston, United States.

Hypomethylating Agents vs. Intensive Chemotherapy for Acute Myeloid Leukemia

18+
All Sexes
Houston, TX
This is a therapeutic intervention trial evaluating the clinical utility of a novel blood-based epigenetic biomarker-genome-wide 5-hydroxymethylcytosine (5hmC) in cell-free DNA (cfDNA)-for assessing measurable residual disease (MRD) in patients with newly diagnosed acute myeloid leukemia (AML). The study compares the efficacy of hypomethylating agent (HMA)-based therapy versus intensive induction chemotherapy, using the 5hmC biomarker to guide post-induction treatment decisions. Approximately 112 adult patients will be enrolled and assigned to treatment arms based on a stratified sampling scheme. Blood samples will be collected at defined intervals to assess MRD status. Primary endpoints include minimal residual disease (MRD) negativity rate, duration of remission, event-free survival (EFS), and overall survival (OS).
Phase 2
Waitlist Available
Houston Methodist Neal Cancer CenterShilpan Shah, MD
Have you considered Myleran clinical trials? We made a collection of clinical trials featuring Myleran, we think they might fit your search criteria.Go to Trials
Image of Yale University School of Medicine in New Haven, United States.

Ziftomenib for AML

18+
All Sexes
New Haven, CT
Ziftomenib is an investigational drug in development for the treatment of patients with acute myeloid leukemia (AML) with eligible genetic alterations. Ziftomenib is a type of therapy known to target the menin pathway in cancer cells. This protocol has 2 separate studies that will investigate the benefits and risks of adding ziftomenib to standard-of-care (SOC) AML treatments in patients with certain genetic mutations who have not received any treatment for their AML. In the first study, the Nonintensive Therapy Study, older patients or those with serious medical problems will receive the SOC therapies venetoclax (ven) and azacitidine (aza), plus either ziftomenib or a placebo. In the second study, the Intensive Therapy Study, medically fit patients will receive (a) the SOC therapies cytarabine and daunorubicin, plus either ziftomenib or a placebo during a first treatment phase called induction, (b) cytarabine plus either ziftomenib or a placebo during a second treatment phase called consolidation, and (c) ziftomenib or a placebo during a third treatment phase called maintenance. The physician will determine which study is the appropriate treatment for the patient, but neither the patient nor their physician will know whether the patient has been assigned to receive ziftomenib or a placebo. This design is called "double-blinded".
Phase 3
Recruiting
Yale University School of Medicine (+1 Sites)Kura Oncology, Inc.
Have you considered Myleran clinical trials? We made a collection of clinical trials featuring Myleran, we think they might fit your search criteria.Go to Trials
Image of MD Anderson in Houston, United States.

Cyclophosphamide-Based Prophylaxis for Leukemia

18 - 66
All Sexes
Houston, TX
The purpose of this clinical trial is to compare drug combinations to learn which drugs work best to prevent graft-versus-host-disease (GVHD) in people who have received a stem cell transplant. The source of stem cells is from someone who is not related and has a different blood cell type than the study participant. The researchers will compare the new drug combination to a standard drug combination. They will also learn about the safety of each drug combination. Participants will: * Receive the standard or new drug combination after transplant * Visit the doctor's office for check-ups and tests after transplant that are routine for most transplant patients * Take surveys about physical and emotional well-being * Give blood and stool samples.
Phase 2
Recruiting
MD Anderson (+2 Sites)Incyte Corporation
Image of Children's Hospital of Philadelphia in Philadelphia, United States.

CD45RA Depleted Stem Cell Addback for Leukemia

1 - 25
All Sexes
Philadelphia, PA
The major morbidities of allogeneic hematopoietic stem cell transplant (HSCT) using donors that are not human leukocyte antigen (HLA) matched siblings are graft vs host disease (GVHD) and life- threatening infections. T cell receptor alpha beta (TCRαβ) T lymphocyte depletion and CD19+ B lymphocyte depletion of alternative donor hematopoietic stem cell (HSC) grafts is effective in preventing GVHD, but immune reconstitution may be delayed, increasing the risk of infections. The central hypothesis of this study is that an addback of CD45RO memory T lymphocytes, derived from a fraction of the original donor peripheral stem cell product depleted of CD45RA naïve T lymphocytes, will accelerate immune reconstitution and help decrease the risk of infections in TCRab/CD19 depleted PSCT.
Phase 1 & 2
Recruiting
Children's Hospital of PhiladelphiaTimothy Olson, MD, PhD
Have you considered Myleran clinical trials? We made a collection of clinical trials featuring Myleran, we think they might fit your search criteria.Go to Trials
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security